Stephen Harrison, MD, discusses results from the phase 3 MAESTRO-NASH trial, highlighting resmetirom’s safety and efficacy for NASH resolution and fibrosis improvement.
Stephen Harrison, MD, provides insight into the use of resmetirom for NASH with fibrosis ahead of the thyroid hormone receptor-β selective agonist’s March 14 PDUFA date.
Investigators from the ongoing MAESTRO-NASH trial provided more evidence that resmetirom may be a viable option in a disease state currently without any approved treatments.
The editorial team’s monthly recap of the top news in hepatology features research emphasizing women’s health in liver disease, a look at some less-recognized health benefits associated with achieving SVR, and promising approaches for preventing and treating hepatic conditions.
Although there was a greater prevalence of ALD and MetALD among male study participants, females had a greater risk of mortality from both SLD phenotypes, highlighting a potentially greater impact of alcohol consumption on women with liver disease than men.